Advertisement

Topics

Bristol-Myers Squibb Announces Encouraging Results for Opdivo Plus Investigational IDO1 Inhibitor in Advanced Cancers

11:11 EST 10 Nov 2017 | Speciality Pharma Journal

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced updated results for Opdivo (nivolumab) plus BMS-986205, a selective, once-daily oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor from the ongoing Phase 1/2a dose escalation and expansion study, CA017-003. In the dose escalation phase, the maximum tolerated dose (primary endpoint) of BMS-986205 in combination with Opdivo was 200 mg. Based on safety and pharmacodynamic …

Original Article: Bristol-Myers Squibb Announces Encouraging Results for Opdivo Plus Investigational IDO1 Inhibitor in Advanced Cancers

NEXT ARTICLE

More From BioPortfolio on "Bristol-Myers Squibb Announces Encouraging Results for Opdivo Plus Investigational IDO1 Inhibitor in Advanced Cancers"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...